Viridian Therapeutics, Inc./DE Research and Development Expense (Excluding Acquired in Process Cost)
Viridian Therapeutics, Inc./DE (VRDN) reported Research and Development Expense (Excluding Acquired in Process Cost) of $71.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE research and development expense (excluding acquired in process cost) for the quarter ending 2026-06-30 was $71.58M, a 17.37% decline year-over-year.
- Viridian Therapeutics, Inc./DE research and development expense (excluding acquired in process cost) for the quarter ending 2026-03-31 was $77.63M, a 1.04% increase year-over-year.
- Viridian Therapeutics, Inc./DE research and development expense (excluding acquired in process cost) for the quarter ending 2025-12-31 was $89.21M, a 23.97% increase year-over-year.
- Viridian Therapeutics, Inc./DE research and development expense (excluding acquired in process cost) for the quarter ending 2025-09-30 was $86.26M, a 24.73% increase year-over-year.
- Viridian Therapeutics, Inc./DE research and development expense (excluding acquired in process cost) for fiscal 2025 was $338.93M, a 42.26% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE research and development expense (excluding acquired in process cost) for fiscal 2024 was $238.25M, a 49.13% increase from fiscal 2023.
- Viridian Therapeutics, Inc./DE research and development expense (excluding acquired in process cost) for fiscal 2023 was $159.76M, a 58.35% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE research and development expense (excluding acquired in process cost) for fiscal 2022 was $100.89M, a 77.36% increase from fiscal 2021.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $71.58M 10-Q · filed 2026-08-06 | $149.21M 10-Q · filed 2026-08-06 | $238.42M derived: sum of 3 quarters · filed 2026-08-06 | $324.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $77.63M 10-Q · filed 2026-05-05 | $166.84M derived: sum of 2 quarters · filed 2026-05-05 | $253.10M derived: sum of 3 quarters · filed 2026-05-05 | $339.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $89.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $175.47M derived: sum of 2 quarters · filed 2026-02-26 | $262.10M derived: sum of 3 quarters · filed 2026-08-06 | $338.93M 10-K · filed 2026-02-26 |
| 2025-09-30 | $86.26M 10-Q · filed 2025-11-05 | $172.89M derived: sum of 2 quarters · filed 2026-08-06 | $249.72M 10-Q · filed 2025-11-05 | $321.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $86.63M 10-Q · filed 2026-08-06 | $163.46M 10-Q · filed 2026-08-06 | $235.42M derived: sum of 3 quarters · filed 2026-08-06 | $304.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $76.83M 10-Q · filed 2026-05-05 | $148.79M derived: sum of 2 quarters · filed 2026-05-05 | $217.95M derived: sum of 3 quarters · filed 2026-05-05 | $274.15M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $71.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $141.12M derived: sum of 2 quarters · filed 2026-02-26 | $197.31M derived: sum of 3 quarters · filed 2026-02-26 | $238.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | $69.16M 10-Q · filed 2025-11-05 | $125.35M derived: sum of 2 quarters · filed 2025-11-05 | $166.29M 10-Q · filed 2025-11-05 | $204.85M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $56.19M 10-Q · filed 2025-08-06 | $97.14M 10-Q · filed 2025-08-06 | $135.69M derived: sum of 3 quarters · filed 2026-02-26 | $166.08M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $40.94M 10-Q · filed 2025-05-06 | $79.50M derived: sum of 2 quarters · filed 2026-02-26 | $109.89M derived: sum of 3 quarters · filed 2026-02-26 | $149.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $38.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $68.94M derived: sum of 2 quarters · filed 2026-02-26 | $109.03M derived: sum of 3 quarters · filed 2026-02-26 | $159.76M 10-K · filed 2026-02-26 |
| 2023-09-30 | $30.39M 10-Q · filed 2024-11-12 | $70.47M derived: sum of 2 quarters · filed 2024-11-12 | $121.21M 10-Q · filed 2024-11-12 | $160.53M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $40.08M 10-Q · filed 2024-08-08 | $90.82M 10-Q · filed 2024-08-08 | $130.14M derived: sum of 3 quarters · filed 2025-03-03 | $152.26M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $50.74M 10-Q · filed 2024-05-08 | $90.06M derived: sum of 2 quarters · filed 2025-03-03 | $112.18M derived: sum of 3 quarters · filed 2025-03-03 | $133.89M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $39.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $61.44M derived: sum of 2 quarters · filed 2025-03-03 | $83.15M derived: sum of 3 quarters · filed 2025-03-03 | $100.89M 10-K · filed 2025-03-03 |
| 2022-09-30 | $22.12M 10-Q · filed 2023-11-13 | $43.83M derived: sum of 2 quarters · filed 2023-11-13 | $61.58M 10-Q · filed 2023-11-13 | $83.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $21.71M 10-Q · filed 2023-08-08 | $39.46M 10-Q · filed 2023-08-08 | $61.85M derived: sum of 3 quarters · filed 2024-02-27 | $69.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $17.75M 10-Q · filed 2023-05-10 | $40.14M derived: sum of 2 quarters · filed 2024-02-27 | $48.26M derived: sum of 3 quarters · filed 2024-02-27 | $60.83M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $22.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $30.52M derived: sum of 2 quarters · filed 2024-02-27 | $43.08M derived: sum of 3 quarters · filed 2024-02-27 | $56.89M 10-K · filed 2024-02-27 |
| 2021-09-30 | $8.12M 10-Q · filed 2022-11-14 | $20.69M derived: sum of 2 quarters · filed 2022-11-14 | $34.49M 10-Q · filed 2022-11-14 | $49.75M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $12.56M 10-Q · filed 2022-08-15 | $26.37M 10-Q · filed 2022-08-15 | $41.63M derived: sum of 3 quarters · filed 2022-08-15 | $44.74M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $13.81M 10-Q · filed 2022-05-13 | $29.06M derived: sum of 2 quarters · filed 2022-05-13 | $32.17M derived: sum of 3 quarters · filed 2022-05-13 | $36.01M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $15.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $18.36M derived: sum of 2 quarters · filed 2022-03-11 | $22.20M derived: sum of 3 quarters · filed 2022-03-11 | $28.30M 10-K · filed 2022-03-11 |
| 2020-09-30 | $3.11M 10-Q · filed 2021-11-05 | $6.95M derived: sum of 2 quarters · filed 2021-11-05 | $13.05M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $3.84M 10-Q · filed 2021-08-12 | $9.94M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $6.10M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $34.79M 10-K · filed 2021-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |